Latest news

The number of registered shares and votes in Nanologica AB has changed during the month of June following the registration of exercised warrants of series TO5. In 2024, Nanologica issued a total of 11,044,654 warrants of series TO5 within the framework of a rights issue of units. During the period May 7, 2025 to May 21, 2025, holders of warrants of series TO5 have had the right to subscribe for shares by virtue of warrants.

The Board of Directors of Nanologica AB (publ) (“Nanologica” or the “Company”) unanimously  recommends the shareholders of Nanologica not to  accept the mandatory cash offer made by Flerie Invest AB (“Flerie”) on May 23, 2025. This statement is made by the Board of Directors of Nanologica in accordance with section II.19 of the Takeover Rules for Nasdaq Stockholm (the “Takeover Rules””). Background According to the Swedish Securities Council’s statement AMN 2024:62, Flerie received an exemption

Nanologica has received an order for the company’s silica-based purification media NLAB Saga® from a new customer in the US. The customer is a manufacturer of peptide drugs, and the order relates to evaluation of NLAB Saga® on a production scale. This is Nanologica’s first order in the North American market for evaluation of the company’s silica at production scale. The order value is USD 140,700, which corresponds to appx. SEK 1.3 million at today’s

Nanologica AB’s (publ) (“Nanologica”) main owner Flerie Invest AB (“Flerie”) has today, May 23, 2025, made a mandatory cash offer of SEK 1.00 per share to the shareholders of Nanologica (the “Offer”). The offer is made in accordance with the rules on mandatory bid due to the acquisition of additional shares in Nanologica by Flerie on April 25, 2025. According to the Swedish Securities Council’s statement AMN 2024:62, Flerie received an exemption from the mandatory